Cover Image
Market Research Report
Product code 
613118

Human Insulin Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 176 Pages | Delivery time: 2-3 business days

Price

Back to Top
Human Insulin Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 176 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The Human Insulin Drugs Market is expected to register a CAGR of 4.19% during the forecast period of 2020-2025 and is estimated to reach USD 29.9 billion by 2025. Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world. Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes. Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.

Key Market Trends

Growing Diabetes Prevalence Driving the Market

Approximately, 100 million people around the world need insulin, including all the people suffering from type-1 diabetes, and 10-25% of people with type-2 diabetes. Although insulin has been used in the treatment of diabetes across the world for over 90 years, more than half of the population in need of insulin today, still, cannot afford or access it. People with type-1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle, to prevent complications. The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients' use, curbing out maximum side effects, and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the global market for insulin therapeutics.

North America Dominates the Market

North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region because of a sedentary lifestyle. The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself. The United States accounts for the highest sales of the long-acting insulin, Lantus, across the world. The majority of diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market. The traditional North American human insulin drugs market is expected to grow during the forecast period, due to its economic affordability by patients. Humulin holds the highest market share, followed by Novolin. There are no generic competitors for the traditional North American human insulin drugs market in the United States.

Competitive Landscape

The global human insulin market is highly consolidated with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine).

Insulins under development:

Novo Nordisk is developing a first once-weekly long-acting insulin (LAI287) which is currently in phase 2. The insulin is indicated for both type-1 and type-2 diabetes patients. Eli Lilly is developing a long-acting insulin-Fc (LY3209590). "Basal insulin-Fc" is a large molecule comprised of engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.

Oral Insulin's Drugs will boost the market:

Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 54429

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)
      • 5.1.1.1 Lantus (Insulin glargine)
      • 5.1.1.2 Levemir (Insulin detemir)
      • 5.1.1.3 Toujeo (Insulin glargine)
      • 5.1.1.4 Tresiba (Insulin degludec)
      • 5.1.1.5 Basaglar (Insulin glargine)
    • 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)
      • 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
      • 5.1.2.2 Humalog (Insulin lispro)
      • 5.1.2.3 Apidra (Insulin glulisine)
      • 5.1.2.4 FIASP (Insulin aspart)
      • 5.1.2.5 Admelog (Insulin lispro)
    • 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)
      • 5.1.3.1 Novolin/Actrapid/Insulatard
      • 5.1.3.2 Humulin
      • 5.1.3.3 Insuman
    • 5.1.4 Combination Insulins (Value and Volume, 2012-2025)
      • 5.1.4.1 NovoMix (Biphasic Insulin aspart)
      • 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
      • 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)
      • 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
    • 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)
      • 5.1.5.1 Insulin Glargine Biosimilars
      • 5.1.5.2 Human Insulin Biosimilars
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012-2025)
      • 5.2.1.1.1 Basal or Long-acting Insulins
      • 5.2.1.1.2 Bolus or Fast-acting Insulins
      • 5.2.1.1.3 Traditional Human Insulins
      • 5.2.1.1.4 Combination Insulins
      • 5.2.1.1.5 Biosimilar Insulins
      • 5.2.1.2 Canada (Value and Volume, 2012-2025)
      • 5.2.1.2.1 Basal or Long-acting Insulins
      • 5.2.1.2.2 Bolus or Fast-acting Insulins
      • 5.2.1.2.3 Traditional Human Insulins
      • 5.2.1.2.4 Combination Insulins
      • 5.2.1.2.5 Biosimilar Insulins
      • 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)
      • 5.2.1.3.1 Basal or Long-acting Insulins
      • 5.2.1.3.2 Bolus or Fast-acting Insulins
      • 5.2.1.3.3 Traditional Human Insulins
      • 5.2.1.3.4 Combination Insulins
      • 5.2.1.3.5 Biosimilar Insulins
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012-2025)
      • 5.2.2.1.1 Basal or Long-acting Insulins
      • 5.2.2.1.2 Bolus or Fast-acting Insulins
      • 5.2.2.1.3 Traditional Human Insulins
      • 5.2.2.1.4 Combination Insulins
      • 5.2.2.1.5 Biosimilar Insulins
      • 5.2.2.2 Germany (Value and Volume, 2012-2025)
      • 5.2.2.2.1 Basal or Long-acting Insulins
      • 5.2.2.2.2 Bolus or Fast-acting Insulins
      • 5.2.2.2.3 Traditional Human Insulins
      • 5.2.2.2.4 Combination Insulins
      • 5.2.2.2.5 Biosimilar Insulins
      • 5.2.2.3 Italy (Value and Volume, 2012-2025)
      • 5.2.2.3.1 Basal or Long-acting Insulins
      • 5.2.2.3.2 Bolus or Fast-acting Insulins
      • 5.2.2.3.3 Traditional Human Insulins
      • 5.2.2.3.4 Combination Insulins
      • 5.2.2.3.5 Biosimilar Insulins
      • 5.2.2.4 Spain (Value and Volume, 2012-2025)
      • 5.2.2.4.1 Basal or Long-acting Insulins
      • 5.2.2.4.2 Bolus or Fast-acting Insulins
      • 5.2.2.4.3 Traditional Human Insulins
      • 5.2.2.4.4 Combination Insulins
      • 5.2.2.4.5 Biosimilar Insulins
      • 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)
      • 5.2.2.5.1 Basal or Long-acting Insulins
      • 5.2.2.5.2 Bolus or Fast-acting Insulins
      • 5.2.2.5.3 Traditional Human Insulins
      • 5.2.2.5.4 Combination Insulins
      • 5.2.2.5.5 Biosimilar Insulins
      • 5.2.2.6 Russia (Value and Volume, 2012-2025)
      • 5.2.2.6.1 Basal or Long-acting Insulins
      • 5.2.2.6.2 Bolus or Fast-acting Insulins
      • 5.2.2.6.3 Traditional Human Insulins
      • 5.2.2.6.4 Combination Insulins
      • 5.2.2.6.5 Biosimilar Insulins
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)
      • 5.2.2.7.1 Basal or Long-acting Insulins
      • 5.2.2.7.2 Bolus or Fast-acting Insulins
      • 5.2.2.7.3 Traditional Human Insulins
      • 5.2.2.7.4 Combination Insulins
      • 5.2.2.7.5 Biosimilar Insulins
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012-2025)
      • 5.2.3.1.1 Basal or Long-acting Insulins
      • 5.2.3.1.2 Bolus or Fast-acting Insulins
      • 5.2.3.1.3 Traditional Human Insulins
      • 5.2.3.1.4 Combination Insulins
      • 5.2.3.1.5 Biosimilar Insulins
      • 5.2.3.2 Brazil (Value and Volume, 2012-2025)
      • 5.2.3.2.1 Basal or Long-acting Insulins
      • 5.2.3.2.2 Bolus or Fast-acting Insulins
      • 5.2.3.2.3 Traditional Human Insulins
      • 5.2.3.2.4 Combination Insulins
      • 5.2.3.2.5 Biosimilar Insulins
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)
      • 5.2.3.3.1 Basal or Long-acting Insulins
      • 5.2.3.3.2 Bolus or Fast-acting Insulins
      • 5.2.3.3.3 Traditional Human Insulins
      • 5.2.3.3.4 Combination Insulins
      • 5.2.3.3.5 Biosimilar Insulins
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012-2025)
      • 5.2.4.1.1 Basal or Long-acting Insulins
      • 5.2.4.1.2 Bolus or Fast-acting Insulins
      • 5.2.4.1.3 Traditional Human Insulins
      • 5.2.4.1.4 Combination Insulins
      • 5.2.4.1.5 Biosimilar Insulins
      • 5.2.4.2 South Korea (Value and Volume, 2012-2025)
      • 5.2.4.2.1 Basal or Long-acting Insulins
      • 5.2.4.2.2 Bolus or Fast-acting Insulins
      • 5.2.4.2.3 Traditional Human Insulins
      • 5.2.4.2.4 Combination Insulins
      • 5.2.4.2.5 Biosimilar Insulins
      • 5.2.4.3 China (Value and Volume, 2012-2025)
      • 5.2.4.3.1 Basal or Long-acting Insulins
      • 5.2.4.3.2 Bolus or Fast-acting Insulins
      • 5.2.4.3.3 Traditional Human Insulins
      • 5.2.4.3.4 Combination Insulins
      • 5.2.4.3.5 Biosimilar Insulins
      • 5.2.4.4 India (Value and Volume, 2012-2025)
      • 5.2.4.4.1 Basal or Long-acting Insulins
      • 5.2.4.4.2 Bolus or Fast-acting Insulins
      • 5.2.4.4.3 Traditional Human Insulins
      • 5.2.4.4.4 Combination Insulins
      • 5.2.4.4.5 Biosimilar Insulins
      • 5.2.4.5 Australia (Value and Volume, 2012-2025)
      • 5.2.4.5.1 Basal or Long-acting Insulins
      • 5.2.4.5.2 Bolus or Fast-acting Insulins
      • 5.2.4.5.3 Traditional Human Insulins
      • 5.2.4.5.4 Combination Insulins
      • 5.2.4.5.5 Biosimilar Insulins
      • 5.2.4.6 Vietnam (Value and Volume, 2012-2025)
      • 5.2.4.6.1 Basal or Long-acting Insulins
      • 5.2.4.6.2 Bolus or Fast-acting Insulins
      • 5.2.4.6.3 Traditional Human Insulins
      • 5.2.4.6.4 Combination Insulins
      • 5.2.4.6.5 Biosimilar Insulins
      • 5.2.4.7 Malaysia (Value and Volume, 2012-2025)
      • 5.2.4.7.1 Basal or Long-acting Insulins
      • 5.2.4.7.2 Bolus or Fast-acting Insulins
      • 5.2.4.7.3 Traditional Human Insulins
      • 5.2.4.7.4 Combination Insulins
      • 5.2.4.7.5 Biosimilar Insulins
      • 5.2.4.8 Indonesia (Value and Volume, 2012-2025)
      • 5.2.4.8.1 Basal or Long-acting Insulins
      • 5.2.4.8.2 Bolus or Fast-acting Insulins
      • 5.2.4.8.3 Traditional Human Insulins
      • 5.2.4.8.4 Combination Insulins
      • 5.2.4.8.5 Biosimilar Insulins
      • 5.2.4.9 Philippines (Value and Volume, 2012-2025)
      • 5.2.4.9.1 Basal or Long-acting Insulins
      • 5.2.4.9.2 Bolus or Fast-acting Insulins
      • 5.2.4.9.3 Traditional Human Insulins
      • 5.2.4.9.4 Combination Insulins
      • 5.2.4.9.5 Biosimilar Insulins
      • 5.2.4.10 Thailand (Value and Volume, 2012-2025)
      • 5.2.4.10.1 Basal or Long-acting Insulins
      • 5.2.4.10.2 Bolus or Fast-acting Insulins
      • 5.2.4.10.3 Traditional Human Insulins
      • 5.2.4.10.4 Combination Insulins
      • 5.2.4.10.5 Biosimilar Insulins
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)
      • 5.2.4.11.1 Basal or Long-acting Insulins
      • 5.2.4.11.2 Bolus or Fast-acting Insulins
      • 5.2.4.11.3 Traditional Human Insulins
      • 5.2.4.11.4 Combination Insulins
      • 5.2.4.11.5 Biosimilar Insulins
    • 5.2.5 Middle-East and Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)
      • 5.2.5.1.1 Basal or Long-acting Insulins
      • 5.2.5.1.2 Bolus or Fast-acting Insulins
      • 5.2.5.1.3 Traditional Human Insulins
      • 5.2.5.1.4 Combination Insulins
      • 5.2.5.1.5 Biosimilar Insulins
      • 5.2.5.2 Iran (Value and Volume, 2012-2025)
      • 5.2.5.2.1 Basal or Long-acting Insulins
      • 5.2.5.2.2 Bolus or Fast-acting Insulins
      • 5.2.5.2.3 Traditional Human Insulins
      • 5.2.5.2.4 Combination Insulins
      • 5.2.5.2.5 Biosimilar Insulins
      • 5.2.5.3 Egypt (Value and Volume, 2012-2025)
      • 5.2.5.3.1 Basal or Long-acting Insulins
      • 5.2.5.3.2 Bolus or Fast-acting Insulins
      • 5.2.5.3.3 Traditional Human Insulins
      • 5.2.5.3.4 Combination Insulins
      • 5.2.5.3.5 Biosimilar Insulins
      • 5.2.5.4 Oman (Value and Volume, 2012-2025)
      • 5.2.5.4.1 Basal or Long-acting Insulins
      • 5.2.5.4.2 Bolus or Fast-acting Insulins
      • 5.2.5.4.3 Traditional Human Insulins
      • 5.2.5.4.4 Combination Insulins
      • 5.2.5.4.5 Biosimilar Insulins
      • 5.2.5.5 South Africa (Value and Volume, 2012-2025)
      • 5.2.5.5.1 Basal or Long-acting Insulins
      • 5.2.5.5.2 Bolus or Fast-acting Insulins
      • 5.2.5.5.3 Traditional Human Insulins
      • 5.2.5.5.4 Combination Insulins
      • 5.2.5.5.5 Biosimilar Insulins
      • 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)
      • 5.2.5.6.1 Basal or Long-acting Insulins
      • 5.2.5.6.2 Bolus or Fast-acting Insulins
      • 5.2.5.6.3 Traditional Human Insulins
      • 5.2.5.6.4 Combination Insulins
      • 5.2.5.6.5 Biosimilar Insulins

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2025)
  • 6.2 Type 2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk A/S
      • 7.1.1.1 Overview
      • 7.1.1.2 Products and Strategies
      • 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.1.4 Ratio Analysis (5 Years)
      • 7.1.1.5 Strength and Stability Analysis (5 Years)
      • 7.1.1.6 Recent Developments
    • 7.1.2 Sanofi S.A.
      • 7.1.2.1 Overview
      • 7.1.2.2 Products and Strategies
      • 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.2.4 Ratio Analysis (5 Years)
      • 7.1.2.5 Strength and Stability Analysis (5 Years)
      • 7.1.2.6 Recent Developments
    • 7.1.3 Eli Lilly and Company
      • 7.1.3.1 Overview
      • 7.1.3.2 Products and Strategies
      • 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.3.4 Ratio Analysis (5 Years)
      • 7.1.3.5 Strength and Stability Analysis (5 Years)
      • 7.1.3.6 Recent Developments
    • 7.1.4 Biocon Limited
      • 7.1.4.1 Overview
      • 7.1.4.2 Products and Strategies
      • 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.4.4 Ratio Analysis (5 Years)
      • 7.1.4.5 Strength and Stability Analysis (5 Years)
      • 7.1.4.6 Recent Developments
    • 7.1.5 Pfizer Inc.
      • 7.1.5.1 Overview
      • 7.1.5.2 Products and Strategies
      • 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.5.4 Ratio Analysis (5 Years)
      • 7.1.5.5 Strength and Stability Analysis (5 Years)
      • 7.1.5.6 Recent Developments
    • 7.1.6 Wockhardt
      • 7.1.6.1 Overview
      • 7.1.6.2 Products and Strategies
      • 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.6.4 Ratio Analysis (5 Years)
      • 7.1.6.5 Strength and Stability Analysis (5 Years)
      • 7.1.6.6 Recent Developments
    • 7.1.7 Julphar
      • 7.1.7.1 Overview
      • 7.1.7.2 Products and Strategies
      • 7.1.7.3 Recent Developments
    • 7.1.8 Exir
      • 7.1.8.1 Overview
      • 7.1.8.2 Products and Strategies
      • 7.1.8.3 Recent Developments
    • 7.1.9 Sedico
      • 7.1.9.1 Overview
      • 7.1.9.2 Products and Strategies
      • 7.1.9.3 Recent Developments
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk AS
    • 7.2.2 Sanofi Aventis
    • 7.2.3 Eli Lilly
    • 7.2.4 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS